Navigation Links
FDA Clears Biospace med's Revolutionary Low Dose Xray Imager
Date:10/9/2007

Technology Provides a 'Total Solution' to Orthopedic Imaging

PARIS and ATLANTA, Oct. 9 /PRNewswire/ -- Biospace med today announced that it has received 510k clearance from the Food and Drug Administration (FDA) to market EOS, a new digital Xray imager in the United States for 2D imaging use.

EOS 2D|3D technology is part of a total solution to orthopedic imaging allowing images to be obtained with a low dose of radiation and is capable of long length digital imaging, permitting full-body, uninterrupted digital imaging with a single scan. Information submitted to FDA in support of Biospace med's marketing application demonstrated up to 10 times reduction in dose when compared with commercially available film systems -- without compromising image quality.

Other features that set EOS apart from traditional Xray or Computed Tomography (CT) are:

-- Captures a full or partial body image

-- Large reduction in radiation dose

-- Multi-planar (frontal and lateral) images are obtained simultaneously

in an upright, weight bearing position (unavailable in CT)

Whole body, standing position imaging is especially valued by orthopedic surgeons when examining spine and joint alignment, as it provides a more comprehensive clinical view.

"EOS represents an advancement in orthopedic imaging, integrating benefits previously unavailable in the marketplace," says Marie Meynadier, CEO of Biospace med. "Physicians will now be able to obtain accurate images while advancing the cause of lowering radiation dose to patients."

EOS is based upon a patented particle detector technology for which Georges Charpak received the Nobel Prize in Physics. Along with Charpak, Dr. Jean Dubousset, a world-renowned French pediatric orthopedic surgeon, also helped design EOS.

"The low dose, weight bearing images offer physicians a global view of the entire body and an understanding of the relationships that exist between joints," Dr. Dubousset said. "This insight into balance and posture can provide valuable surgical planning information and may reduce the need for higher dose exams."

EOS differs in several other respects from traditional film, digital Xray or CT. Its use of slot scanning technology eliminates vertical distortion that is common with traditional Xray systems. In addition, EOS enables long length digital imaging without the need for digital stitching -- all at a reduced dose. The simultaneous bi-plane image acquisition (front and side images acquired at the same time) eliminates the need for taking a second view and can save time.

According to a 2007 American College of Radiology study the benefits of diagnostic imaging are immense(1) however, information gleaned from the International Commission on Radiological Protection has reported that CT doses can indeed approach or exceed levels that have been shown to result in an increase in cancer.(2)

In addition, a June 19, 2007, New York Times article reported that the U.S. per capita radiation dose from clinical imaging exams rose by 600 percent between 1980 and 2006, with a major contributor being CT exams, whose numbers have increased over 20 times during this period.

The low dose benefits of EOS may be particularly useful for patients with spinal disorders, such as scoliosis, a spinal deformity condition affecting over 900,000 people in the U.S. alone. Scoliosis patients are typically required to undergo numerous radiographic exams to monitor progression of the disease as well as treatment effectiveness. A retrospective study of over 5,500 female scoliosis patients who received an average of 25 radiographs and whose initial diagnoses spanned a period of 50 years concluded that a statistically significant 70 percent excess risk of dying of breast cancer was observed compared to the general population.(3)

"We are thrilled that the FDA has cleared EOS for the U.S. market after our many years of hard work and dedication," Meynadier added. "Providing physicians the EOS option for orthopedic imaging through both the Nobel Prize technology and the efforts of the entire team makes this a very exciting moment."

The 3D Workstation*

The company is also developing an advanced workstation for the U.S. market, designed to generate a 3D skeletal reconstruction from the two simultaneous planar images. This planned product will also feature automatic measurement software designed to calculate a variety of measurements and angle calculations between individual bones and joints, potentially helping to evaluate global balance and posture. Currently, the 3D workstation is commercially available only in Europe and Canada.

About Biospace med

Biospace med was founded on a unique partnership between a Nobel Prize-winning physicist, a team of biomedical engineers, orthopedic surgeons, and radiologists who have developed a complete orthopedic imaging solution. The company's lead product, EOS ultra low dose 2D|3D Xray imager, allows full-body imaging of patients in a weight-bearing position that will enable global assessment of balance and posture. EOS is a total solution in orthopedic imaging now available in the U.S since receiving FDA 510k clearance. An advanced workstation*, designed to generate a 3D skeletal image from the two planar images, is under development. The company has corporate headquarters in Paris and Atlanta with an office in Montreal, and is targeting a $2 billion orthopedic imaging marketplace. Biospace med is venture-backed by a pool of investors led by Edmond de Rothschild Investment Partners. Learn more at http://www.biospacemed.com.

* EOS 3D is currently commercially available in Europe and Canada only,

and is not part of the current FDA clearance.

(1) American College of Radiology White Paper on Radiation Dose in

Medicine, J Am Coll Radiol 2007; 4:272-284

(2) Rabin, RC, "With Rise in Radiation Exposure, Experts Urge Caution,"

New York Times, June 19, 2007.

http://www.nytimes.com/2007/06/19/health/19cons.html

(3) Doody, MM, et. al, Breast Cancer Mortality After Diagnostic Radiology:

Findings from the US Scoliosis Cohort Study, SPINE, vol25, no16, pgs

2052-2063, 2000


'/>"/>
SOURCE Biospace med
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. FDA Clears GE Healthcares New Bone Density System
2. EraGens Revolutionary Genomic-Based Technologies
3. Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager
4. Ettan DIGE Imager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... NBIX ) today announced its financial results for the quarter ... --> For the fourth quarter of 2015, the ... per share, compared to a net loss of $19.4 million, or ... the year ended December 31, 2015, the Company reported a net ... to a net loss of $60.5 million, or $0.81 loss per ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit organization ... researched, developed, marketed and made accessible to patients around the ... had named the publication of the Good Pharma ... publication is also featured as one of BMJ Open ... last year that are most frequently read. Ed ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
Breaking Biology Technology:
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):